Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

被引:2
作者
Dicitore, Alessandra [1 ]
Gaudenzi, Germano [2 ]
Carra, Silvia [3 ]
Cantone, Maria Celeste [2 ]
Oldani, Monica [2 ]
Saronni, Davide [1 ]
Borghi, Maria Orietta [4 ,5 ]
Grotteschi, Jacopo [1 ]
Persani, Luca [1 ,3 ]
Vitale, Giovanni [1 ,2 ]
机构
[1] Univ Milan, Dept Med Biotechnol & Translat Med, I-20122 Milan, Italy
[2] Ist Auxol Italiano, IRCCS, Lab Geriatr & Oncol Neuroendocrinol Res, Milan I-20145, Italy
[3] Ist Auxol Italiano, IRCCS, Lab Endocrine & Metab Res, I-20145 Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[5] Ist Auxol Italiano, IRCCS, Expt Lab Immuno Rheumatol, I-20145 Milan, Italy
关键词
lung carcinoid; tyrosine kinase inhibitors; axitinib; cell cycle; apoptosis; zebrafish; tumor xenograft; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II; NEUROENDOCRINE TUMORS; MICROVASCULAR DENSITY; ENDOCRINE TUMORS; OPEN-LABEL; ANGIOGENESIS; EXPRESSION; SUNITINIB;
D O I
10.3390/cancers15225375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential antitumor effects of axitinib using both in vitro (immortalized cell lines) and in vivo (zebrafish) LC models. Axitinib demonstrated significant antitumor activity by reducing cell viability, inducing cell cycle arrest, and promoting cell death. Moreover, axitinib had a notable impact on crucial processes in tumor progression, including tumor-induced angiogenesis and invasiveness.Abstract Lung carcinoids (LCs) comprise well-differentiated neuroendocrine tumors classified as typical (TCs) and atypical (ACs) carcinoids. Unfortunately, curative therapies remain elusive for metastatic LCs, which account for 25-30% of cases. This study evaluated the antitumor activity of axitinib (AXI), a second-generation tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) in human lung TC (NCI-H727, UMC-11, NCI-H835) and AC (NCI-H720) cell lines. In vitro and in vivo (zebrafish) assays were performed following AXI treatment to gather several read-outs about cell viability, cell cycle, the secretion of proangiogenic factors, apoptosis, tumor-induced angiogenesis and migration. AXI demonstrated relevant antitumor activity in human LC cells, with pronounced effects observed in UMC-11 and NCI-H720, characterized by cell cycle perturbation and apoptosis induction. AXI significantly hindered tumor induced-angiogenesis in Tg(fli1a:EGFP)y1 zebrafish embryos implanted with all LC cell lines and also reduced the invasiveness of NCI-H720 cells, as well as the secretion of several proangiogenic factors. In conclusion, our study provides initial evidence supporting the potential anti-tumor activity of AXI in LC, offering a promising basis for future investigations in mammalian animal models and, eventually, progressing to clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Lung Carcinoids: A Comprehensive Review for Clinicians
    Granberg, Dan
    Juhlin, Carl Christofer
    Falhammar, Henrik
    Hedayati, Elham
    CANCERS, 2023, 15 (22)
  • [42] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Xia, Yong
    Song, Xuejiao
    Li, Deliang
    Ye, Tinghong
    Xu, Youzhi
    Lin, Hongjun
    Meng, Nana
    Li, Guobo
    Deng, Senyi
    Zhang, Shuang
    Liu, Li
    Zhu, Yongxia
    Zeng, Jun
    Lei, Qian
    Pan, Youli
    Wei, Yuquan
    Zhao, Yinglan
    Yu, Luoting
    SCIENTIFIC REPORTS, 2014, 4
  • [43] TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer
    Zhu, Kunshou
    Fang, Weimin
    Chen, Yuanmei
    Lin, Shaofeng
    Chen, Xiaohui
    ONCOLOGY REPORTS, 2014, 32 (03) : 1234 - 1242
  • [44] Antitumor activity of celecoxib with docetaxel on human triple-negative breast cancer cells
    Ajikanari, Oktay
    Miaadi, Elham
    Hedayat, Mohaddeseh
    Jafari, Reza
    Asghari, Rahim
    Zolbanin, Naime Majidi
    GENE REPORTS, 2025, 38
  • [45] ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature
    La Rosa, Stefano
    Volante, Marco
    Uccella, Silvia
    Maragliano, Roberta
    Rapa, Ida
    Rotolo, Nicola
    Inzani, Frediano
    Siciliani, Alessandra
    Granone, Pierluigi
    Rindi, Guido
    Dominioni, Lorenzo
    Capella, Carlo
    Papotti, Mauro
    Sessa, Fausto
    Imperatori, Andrea
    VIRCHOWS ARCHIV, 2019, 475 (05) : 587 - 597
  • [46] Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer
    Bai, Tao
    Dong, Dao-Song
    Pei, Ling
    ONCOLOGY REPORTS, 2014, 31 (05) : 2293 - 2297
  • [47] Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
    Fu, Ying
    Saxu, Rengui
    Ridwan, Kadir Ahmad
    Yao, Jiaping
    Chen, Xiaoxuan
    Xu, Xueping
    Zheng, Weida
    Yu, Peng
    Teng, Yuou
    MOLECULES, 2022, 27 (09):
  • [48] Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    Oechsle, K.
    Honecker, F.
    Cheng, T.
    Mayer, F.
    Czaykowski, P.
    Winquist, E.
    Wood, L.
    Fenner, M.
    Glaesener, S.
    Hartmann, J. T.
    Chi, K.
    Bokemeyer, C.
    Kollmannsberger, C.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2654 - 2660
  • [49] Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma
    Green, Adam L.
    Ramkissoon, Shakti H.
    McCauley, Dilara
    Jones, Kristen
    Perry, Jennifer A.
    Hsu, Jessie Hao-Ru
    Ramkissoon, Lori A.
    Maire, Cecile L.
    Hubbell-Engler, Benjamin
    Knoff, David S.
    Shacham, Sharon
    Ligon, Keith L.
    Kung, Andrew L.
    NEURO-ONCOLOGY, 2015, 17 (05) : 697 - 707
  • [50] Study on antitumor activity of isatin in vivo
    Zhang, Fang
    Wang, Lei
    Zhou, Ming
    Ju, chuanxia
    Yue, Wang
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 61 - 61